脂肪酸酸化障害（FAOD）の世界市場レポート 2025年

脂肪酸酸化障害（FAOD）の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.9％で139億9,000万米ドルに成長すると予想されます。予測期間中の成長は、持続可能なバイオ製品への需要の高まり、個別化医療の採用の増加、FAODの早期診断、研究開発資金の増加、長期的転帰の強化への注力の強化などに起因すると考えられます。予測期間における主な動向としては、遠隔医療サービスの統合、診断や創薬における人工知能の利用、遺伝子検査の進歩、技術革新、患者中心のケアモデルへの移行などが挙げられます。

遺伝子治療に対する需要の高まりは、今後の脂肪酸酸化障害（FAOD）市場の拡大を牽引すると予想されます。遺伝子治療は、病気の治療や予防のために欠陥のある遺伝子を修正したり置き換えたりするものです。遺伝子治療の需要が高まっているのは、根本的な遺伝的原因をターゲットにすることで、遺伝性疾患、がん、希少疾病を治療できる可能性があるためです。このため、バイオテクノロジーへの投資が増加しています。遺伝子治療は、酵素活性を回復させ、エネルギー産生を強化し、疾患の合併症を予防する機能的遺伝子を提供することにより、脂肪酸酸化障害による代謝不全に対処することを目的としています。例えば、2024年4月、米国遺伝子・細胞治療学会は、第4四半期の第III相臨床試験中の遺伝子治療薬の数が10％増加したと報告し、2022年第3四半期以来、四半期ベースで初めてこのような伸びを示しました。その結果、遺伝子治療に対する需要の高まりがFAOD市場の成長を後押ししています。

FAOD市場の企業は、FAOD患者の代謝制御と治療成績を改善するために、ペルオキシソーム増殖因子活性化受容体デルタ（PPARδ）作動薬などの革新的なソリューションを開発しています。PPARδ作動薬は、脂質代謝、炎症、エネルギーバランスの調節に重要な役割を果たすPPARδ受容体を活性化します。このアプローチは、代謝性疾患や心血管疾患に治療効果をもたらす可能性があります。例えば、2023年1月、Reneo Pharmaceuticals Inc.は、長鎖脂肪酸酸化障害（LC-FAOD）に関連する遺伝子型である長鎖3-ヒドロキシアシル-CoA脱水素酵素（LCHAD）欠損症を標的とする治験薬Mavodelpar（REN001）について、米国食品医薬品局（FDA）からファストトラック指定を受けました。PPARδを活性化することにより、Mavodelparはミトコンドリア機能を改善し、エネルギー代謝を高め、LC-FAODに関連する症状を緩和することを目的としています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の脂肪酸酸化障害（FAOD）市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の脂肪酸酸化障害（FAOD）市場：成長率分析
• 世界の脂肪酸酸化障害（FAOD）市場の実績：規模と成長、2019～2024年
• 世界の脂肪酸酸化障害（FAOD）市場の予測：規模と成長、2024～2029年、2034年
• 世界の脂肪酸酸化障害（FAOD）総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の脂肪酸酸化障害（FAOD）市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 長鎖
• 短鎖
• 世界の脂肪酸酸化障害（FAOD）市場：薬剤タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• レボカルニチン
• デキストロース
• リボフラビン
• その他
• 世界の脂肪酸酸化障害（FAOD）市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口
• 静脈内
• 世界の脂肪酸酸化障害（FAOD）市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• ドラッグストア
• オンラインストア
• 世界の脂肪酸酸化障害（FAOD）市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• クリニック
• 製薬会社
• 世界の脂肪酸酸化障害（FAOD）市場：長鎖のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 極長鎖アシルCoA脱水素酵素欠損症（VLCAD）
• 長鎖3-ヒドロキシアシルCoA脱水素酵素欠損症（LCHAD）
• 三機能性タンパク質欠損症（TFP）
• カルニチンパルミトイルトランスフェラーゼII欠損症（CPT II）
• 世界の脂肪酸酸化障害（FAOD）市場：短鎖のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 中鎖アシルCoA脱水素酵素欠損症（MCAD）
• 短鎖アシルCoA脱水素酵素欠損症（SCAD）
• カルニチン吸収障害（CUD）

第7章 地域別・国別分析

• 世界の脂肪酸酸化障害（FAOD）市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の脂肪酸酸化障害（FAOD）市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 脂肪酸酸化障害（FAOD）市場：競合情勢
• 脂肪酸酸化障害（FAOD）市場：企業プロファイル
  • BASF SE Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc Overview, Products and Services, Strategy and Financial Analysis
  • Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • Baxter International Inc Overview, Products and Services, Strategy and Financial Analysis
  • Koninklijke DSM NV Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Ingredion Incorporated
• Lonza Group Ltd
• Roquette Freres SA
• Dr Reddy's Laboratories Limited
• Tate & Lyle PLC
• ANI Pharmaceuticals Inc
• Ultragenyx Pharmaceutical Inc
• Gulshan Polyols Limited
• Hubei Guangji Pharmaceutical Co Ltd
• Omega Laboratories Limited
• Actiza Pharmaceutical Private Limited
• Allmpus Laboratories Private Limited
• Reneo Pharmaceuticals Inc
• Greenwell Lifesciences
• NB Group Co Ltd

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 脂肪酸酸化障害（FAOD）市場2029：新たな機会を提供する国
• 脂肪酸酸化障害（FAOD）市場2029：新たな機会を提供するセグメント
• 脂肪酸酸化障害（FAOD）市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Fatty acid oxidation disorders (FAODs) are a group of rare inherited metabolic conditions that disrupt the body's ability to convert fats into energy due to a lack or malfunction of specific enzymes necessary for fatty acid breakdown. As a result, fatty acids accumulate in the body, leading to severe energy shortages, hypoglycemia, muscle weakness, and potential organ damage, especially during times of fasting or illness.

The primary types of fatty acid oxidation disorders are long-chain and short-chain disorders. Long-chain fatty acid oxidation disorders (LC-FAODs) are conditions where the body cannot properly metabolize long-chain fatty acids for energy, causing energy deficiencies and metabolic disturbances. Treatment options include medications such as levocarnitine, dextrose, riboflavin, and others, which can be administered through oral or intravenous routes. These medications are distributed through hospital pharmacies, retail pharmacies, drugstores, and online platforms, with end users including hospitals, clinics, and pharmaceutical companies.

The fatty acid oxidation disorders (FAODs) market research report is one of a series of new reports from The Business Research Company that provides fatty acid oxidation disorders (FAODs) market statistics, including the fatty acid oxidation disorders (FAODs) industry global market size, regional shares, competitors with the fatty acid oxidation disorders (FAODs) market share, detailed fatty acid oxidation disorders (FAODs) market segments, market trends, and opportunities, and any further data you may need to thrive in the fatty acid oxidation disorders (FAODs) industry. This fatty acid oxidation disorders (FAODs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The fatty acid oxidation disorders (FAODs) market size has grown strongly in recent years. It will grow from $9.55 billion in 2024 to $10.33 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth during the historic period can be attributed to factors such as greater awareness, a rise in the prevalence of rare and genetic disorders, an increasing number of product approvals, enhanced government initiatives, and a growing demand for orphan drugs.

The fatty acid oxidation disorders (FAODs) market size is expected to see strong growth in the next few years. It will grow to $13.99 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth during the forecast period can be attributed to the growing demand for sustainable bio-products, the increasing adoption of personalized medicine, earlier diagnosis of FAODs, rising funding for research and development, and a stronger focus on enhancing long-term outcomes. Key trends in the forecast period include the integration of telehealth services, the use of artificial intelligence in diagnostics and drug discovery, advancements in genetic testing, technological innovations, and a shift towards patient-centric care models.

The growing demand for gene therapy is anticipated to drive the expansion of the fatty acid oxidation disorders (FAODs) market in the future. Gene therapy involves modifying or replacing defective genes to treat or prevent diseases. The rising demand for gene therapy is due to its potential to treat genetic disorders, cancer, and rare diseases by targeting the underlying genetic causes. This has led to significant investments and advancements in biotechnology. Gene therapy aims to address metabolic deficiencies caused by fatty acid oxidation disorders by delivering functional genes to restore enzymatic activity, enhance energy production, and prevent disease complications. For example, in April 2024, the American Society of Gene & Cell Therapy reported a 10% increase in the number of gene therapies in Phase III clinical trials in the fourth quarter, marking the first quarterly growth of this kind since the third quarter of 2022. As a result, the rising demand for gene therapy is fueling the growth of the FAODs market.

Companies in the FAODs market are developing innovative solutions such as peroxisome proliferator-activated receptor delta (PPARδ) agonists to improve metabolic control and treatment outcomes for patients with FAODs. A PPARδ agonist activates the PPARδ receptor, which plays a key role in regulating lipid metabolism, inflammation, and energy balance. This approach may offer therapeutic benefits for metabolic disorders and cardiovascular diseases. For instance, in January 2023, Reneo Pharmaceuticals Inc. received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its investigational drug, Mavodelpar (REN001), which targets long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, a genotype linked to long-chain fatty acid oxidation disorder (LC-FAOD). By activating PPARδ, Mavodelpar aims to improve mitochondrial function, enhance energy metabolism, and alleviate symptoms related to LC-FAOD.

In October 2024, OnKure Therapeutics Inc., a US-based pharmaceutical company, merged with Reneo Pharmaceuticals Inc. in an undisclosed deal. The merger combines OnKure's expertise in precision oncology with Reneo's resources to accelerate the development of targeted therapies for oncogenic PI3Ka mutations, specifically using mutant-selective PI3Ka inhibitors. Reneo Pharmaceuticals specializes in developing treatments for fatty acid oxidation disorders.

Major players in the fatty acid oxidation disorders (FAODs) market are BASF SE, Thermo Fisher Scientific Inc, Takeda Pharmaceutical Company Limited, Baxter International Inc, Koninklijke DSM NV, Ingredion Incorporated, Lonza Group Ltd, Roquette Freres SA, Dr Reddy's Laboratories Limited, Tate & Lyle PLC, ANI Pharmaceuticals Inc, Ultragenyx Pharmaceutical Inc, Gulshan Polyols Limited, Hubei Guangji Pharmaceutical Co Ltd, Omega Laboratories Limited, Actiza Pharmaceutical Private Limited, Allmpus Laboratories Private Limited, Reneo Pharmaceuticals Inc, Greenwell Lifesciences, and NB Group Co Ltd.

Asia-Pacific was the largest region in the fatty acid oxidation disorders (FAODs) market in 2024. The regions covered in fatty acid oxidation disorders (FAODs) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the fatty acid oxidation disorders (FAODs) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The fatty acid oxidation disorders (FAODs) market consists of revenues earned by entities by providing services such as newborn screening and genetic testing, nutritional therapy, remote monitoring, and patient support. The market value includes the value of related goods sold by the service provider or included within the service offering. The fatty acid oxidation disorders (FAODs) market also includes sales of medical foods and supplements, diagnostic and genetic testing kits, and nutritional supplements. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Fatty Acid Oxidation Disorders (FAODs) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on fatty acid oxidation disorders (faods) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for fatty acid oxidation disorders (faods) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The fatty acid oxidation disorders (faods) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Long Chain; Short Chain
• 2) By Drug Type: Levocarnitine; Dextrose; Riboflavin; Other Drug Types
• 3) By Route of Administration: Oral; Intravenous
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Drug Stores; Online Stores
• 5) By End User: Hospitals; Clinics; Pharmaceutical Companies
• Subsegments:
• 1) By Long Chain: Very Long-Chain Acyl-CoA Dehydrogenase Deficiency (VLCAD); Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency (LCHAD); Trifunctional Protein Deficiency (TFP); Carnitine Palmitoyltransferase II Deficiency (CPT II)
• 2) By Short Chain: Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCAD); Short-Chain Acyl-CoA Dehydrogenase Deficiency (SCAD); Carnitine Uptake Defect (CUD)
• Companies Mentioned: BASF SE; Thermo Fisher Scientific Inc; Takeda Pharmaceutical Company Limited; Baxter International Inc; Koninklijke DSM NV
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Fatty Acid Oxidation Disorders (FAODs) Market Characteristics

3. Fatty Acid Oxidation Disorders (FAODs) Market Trends And Strategies

4. Fatty Acid Oxidation Disorders (FAODs) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Fatty Acid Oxidation Disorders (FAODs) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Fatty Acid Oxidation Disorders (FAODs) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Fatty Acid Oxidation Disorders (FAODs) Market Growth Rate Analysis
• 5.4. Global Fatty Acid Oxidation Disorders (FAODs) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Fatty Acid Oxidation Disorders (FAODs) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Fatty Acid Oxidation Disorders (FAODs) Total Addressable Market (TAM)

6. Fatty Acid Oxidation Disorders (FAODs) Market Segmentation

• 6.1. Global Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Long Chain
• Short Chain
• 6.2. Global Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Levocarnitine
• Dextrose
• Riboflavin
• Other Drug Types
• 6.3. Global Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• 6.4. Global Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Stores
• 6.5. Global Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Pharmaceutical Companies
• 6.6. Global Fatty Acid Oxidation Disorders (FAODs) Market, Sub-Segmentation Of Long Chain, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Very Long-Chain Acyl-CoA Dehydrogenase Deficiency (VLCAD)
• Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency (LCHAD)
• Trifunctional Protein Deficiency (TFP)
• Carnitine Palmitoyltransferase II Deficiency (CPT II)
• 6.7. Global Fatty Acid Oxidation Disorders (FAODs) Market, Sub-Segmentation Of Short Chain, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCAD)
• Short-Chain Acyl-CoA Dehydrogenase Deficiency (SCAD)
• Carnitine Uptake Defect (CUD)

7. Fatty Acid Oxidation Disorders (FAODs) Market Regional And Country Analysis

• 7.1. Global Fatty Acid Oxidation Disorders (FAODs) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Fatty Acid Oxidation Disorders (FAODs) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Fatty Acid Oxidation Disorders (FAODs) Market

• 8.1. Asia-Pacific Fatty Acid Oxidation Disorders (FAODs) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Fatty Acid Oxidation Disorders (FAODs) Market

• 9.1. China Fatty Acid Oxidation Disorders (FAODs) Market Overview
• 9.2. China Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Fatty Acid Oxidation Disorders (FAODs) Market

• 10.1. India Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Fatty Acid Oxidation Disorders (FAODs) Market

• 11.1. Japan Fatty Acid Oxidation Disorders (FAODs) Market Overview
• 11.2. Japan Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Fatty Acid Oxidation Disorders (FAODs) Market

• 12.1. Australia Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Fatty Acid Oxidation Disorders (FAODs) Market

• 13.1. Indonesia Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Fatty Acid Oxidation Disorders (FAODs) Market

• 14.1. South Korea Fatty Acid Oxidation Disorders (FAODs) Market Overview
• 14.2. South Korea Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Fatty Acid Oxidation Disorders (FAODs) Market

• 15.1. Western Europe Fatty Acid Oxidation Disorders (FAODs) Market Overview
• 15.2. Western Europe Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Fatty Acid Oxidation Disorders (FAODs) Market

• 16.1. UK Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Fatty Acid Oxidation Disorders (FAODs) Market

• 17.1. Germany Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Fatty Acid Oxidation Disorders (FAODs) Market

• 18.1. France Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Fatty Acid Oxidation Disorders (FAODs) Market

• 19.1. Italy Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Fatty Acid Oxidation Disorders (FAODs) Market

• 20.1. Spain Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Fatty Acid Oxidation Disorders (FAODs) Market

• 21.1. Eastern Europe Fatty Acid Oxidation Disorders (FAODs) Market Overview
• 21.2. Eastern Europe Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Fatty Acid Oxidation Disorders (FAODs) Market

• 22.1. Russia Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Fatty Acid Oxidation Disorders (FAODs) Market

• 23.1. North America Fatty Acid Oxidation Disorders (FAODs) Market Overview
• 23.2. North America Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Fatty Acid Oxidation Disorders (FAODs) Market

• 24.1. USA Fatty Acid Oxidation Disorders (FAODs) Market Overview
• 24.2. USA Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Fatty Acid Oxidation Disorders (FAODs) Market

• 25.1. Canada Fatty Acid Oxidation Disorders (FAODs) Market Overview
• 25.2. Canada Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Fatty Acid Oxidation Disorders (FAODs) Market

• 26.1. South America Fatty Acid Oxidation Disorders (FAODs) Market Overview
• 26.2. South America Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Fatty Acid Oxidation Disorders (FAODs) Market

• 27.1. Brazil Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Fatty Acid Oxidation Disorders (FAODs) Market

• 28.1. Middle East Fatty Acid Oxidation Disorders (FAODs) Market Overview
• 28.2. Middle East Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Fatty Acid Oxidation Disorders (FAODs) Market

• 29.1. Africa Fatty Acid Oxidation Disorders (FAODs) Market Overview
• 29.2. Africa Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Fatty Acid Oxidation Disorders (FAODs) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Fatty Acid Oxidation Disorders (FAODs) Market Competitive Landscape And Company Profiles

• 30.1. Fatty Acid Oxidation Disorders (FAODs) Market Competitive Landscape
• 30.2. Fatty Acid Oxidation Disorders (FAODs) Market Company Profiles
  • 30.2.1. BASF SE Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Thermo Fisher Scientific Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Baxter International Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Koninklijke DSM NV Overview, Products and Services, Strategy and Financial Analysis

31. Fatty Acid Oxidation Disorders (FAODs) Market Other Major And Innovative Companies

• 31.1. Ingredion Incorporated
• 31.2. Lonza Group Ltd
• 31.3. Roquette Freres SA
• 31.4. Dr Reddy's Laboratories Limited
• 31.5. Tate & Lyle PLC
• 31.6. ANI Pharmaceuticals Inc
• 31.7. Ultragenyx Pharmaceutical Inc
• 31.8. Gulshan Polyols Limited
• 31.9. Hubei Guangji Pharmaceutical Co Ltd
• 31.10. Omega Laboratories Limited
• 31.11. Actiza Pharmaceutical Private Limited
• 31.12. Allmpus Laboratories Private Limited
• 31.13. Reneo Pharmaceuticals Inc
• 31.14. Greenwell Lifesciences
• 31.15. NB Group Co Ltd

32. Global Fatty Acid Oxidation Disorders (FAODs) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Fatty Acid Oxidation Disorders (FAODs) Market

34. Recent Developments In The Fatty Acid Oxidation Disorders (FAODs) Market

35. Fatty Acid Oxidation Disorders (FAODs) Market High Potential Countries, Segments and Strategies

• 35.1 Fatty Acid Oxidation Disorders (FAODs) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Fatty Acid Oxidation Disorders (FAODs) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Fatty Acid Oxidation Disorders (FAODs) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer